Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Nabriva Therapeutics (NASDAQ: NBRV) announced that CEO Ted Schroeder will present a company overview at the H.C. Wainwright 23rd Annual Virtual Global Investment Conference. The presentation will be available on-demand starting September 13, 2021, at 7:00 A.M. (ET). Interested parties can access it via the 'Investors' section of the company's website under 'Events and Presentations'. Nabriva is known for its innovative anti-infective agents, including XENLETA® and CONTEPO™, aimed at treating serious infections.

DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright 23rd Annual Virtual Global Investment Conference. The presentation will be available on-demand starting Monday, September 13, at 7:00 A.M. (ET).

The presentation may be accessed by visiting the "Investors" section of the Company's website under the "Events and Presentations" tab at www.nabriva.com. A replay of the webcast will be available for 90 days.

About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.

CONTACTS:

For Investors
Kim Anderson
Nabriva Therapeutics plc
ir@nabriva.com 

For Media
Andrea Greif
Ogilvy
andrea.greif@ogilvy.com
914-772-3027

FAQ

When will Nabriva Therapeutics present at the H.C. Wainwright 23rd Annual Virtual Global Investment Conference?

Nabriva Therapeutics will present on September 13, 2021, starting at 7:00 A.M. (ET).

How can I access the Nabriva Therapeutics presentation?

The presentation can be accessed on-demand through the 'Investors' section of Nabriva's website under 'Events and Presentations'.

What products is Nabriva Therapeutics known for?

Nabriva is known for XENLETA® and CONTEPO™, which target serious infections.

What is the ticker symbol for Nabriva Therapeutics?

The ticker symbol for Nabriva Therapeutics is NBRV.

What new developments did Nabriva Therapeutics announce?

Nabriva announced a business update and CEO presentation at the upcoming investment conference.